A Window Study of Ixazomib in Untreated Indolent B-NHL.

Trial Profile

A Window Study of Ixazomib in Untreated Indolent B-NHL.

Phase of Trial: Phase II

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs Ixazomib (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 28 Mar 2016 New drug rituximab is given in combination with ixazomib. Therefore purpose and treatment has been updated according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top